Predicting hepatitis C treatment success

May 8, 2014

Levels of interferon-stimulated genes in the liver and blood could help predict if a patient with hepatitis C will respond to conventional therapy, researchers at Kanazawa University suggest.

A combined therapy using interferons and ribavirin is often used to treat C, but around half of patients are unresponsive and suffer relapse. Previous research has shown that variations in a gene called interleukin 28B (IL28B) render a patient either sensitive to treatment or completely resistant to it. However, the mechanisms relating the IL28B gene to the treatment are not well understood.

Now, Shuichi Kaneko and colleagues at Kanazawa University have discovered that, in therapy-resistant patients, interferon-stimulated gene (ISG) expression is up-regulated in the liver but down-regulated in the blood - a significantly different pattern of ISG expression to therapy-responsive patients.

The team analyzed liver and blood samples from hepatitis C patients taken before treatment, and found that fewer immune cells reached the livers of patients with the therapy-resistant genotype. The team believe this lack of may induce higher levels of other inflammatory proteins, such as WNT5A. Higher WNT5A levels in the therapy-resistant both enhanced the expression of ISGs in the liver and increased hepatitis C viral replication. The researchers hope that further research will clarify these mechanisms with regard to treatment response.

In the meantime, measuring ISG expression patterns in blood and samples could provide a useful way of predicting a patient's response to interferon / ribavirin therapy.

Explore further: Good news for some hard-to-treat hepatitis C patients

More information: Honda, M., Shirasaki, T., Shimakami, T., Sakai, A., Horii, R., Arai, K., Yamashita, T., Sakai, Y., Yamashita, T., Okada, H., Murai, K., Nakamura, M., Mizukoshi, E. and Kaneko, S. (2014), "Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes." Hepatology, 59: 828–838. doi: 10.1002/hep.26788

Related Stories

Good news for some hard-to-treat hepatitis C patients

June 16, 2009

In a multi-center trial led by a Saint Louis University researcher, investigators found that a new combination therapy of daily consensus interferon and ribavirin helps some hepatitis C patients who have not responded to ...

New combination therapy for hepatitis C

May 5, 2014

A new combination therapy allows chronic hepatitis C to be treated in a manner that is less aggressive yet equally efficient. This is the result of a current study, led by primary author Peter Ferenci from the University ...

Recommended for you

Team discovers how Zika virus causes fetal brain damage

August 24, 2016

Infection by the Zika virus diverts a key protein necessary for neural cell division in the developing human fetus, thereby causing the birth defect microcephaly, a team of Yale scientists reported Aug. 24 in the journal ...

Zika infection may affect adult brain cells

August 18, 2016

Concerns over the Zika virus have focused on pregnant women due to mounting evidence that it causes brain abnormalities in developing fetuses. However, new research in mice from scientists at The Rockefeller University and ...

Immune breakthrough: Unscratching poison ivy's rash

August 23, 2016

We all know that a brush with poison ivy leaves us with an itchy painful rash. Now, Monash University and Harvard researchers have discovered the molecular cause of this irritation. The finding brings us a step closer to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.